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1. Introduction 
Lung cancer is leading cause of cancer death in many advanced countries and one of the 
challenging malignancies because of poor prognosis. Lung cancer is traditionally divided 
into two major categories, so called small cell lung carcinoma (SCLC) and non-small cell 
lung carcinoma (NSCLC) because of distinctive prognostic and treatment strategies between 
them. On the other hand, there is a spectrum of tumors called pulmonary neuroendocrine 
(NE) tumors that are thought to originate from neuroendocrine cells in the pulmonary and 
bronchial epithelium. Until recently, pulmonary NE tumors were classified into three 
categories, i.e., typical carcinoid (TC), atypical carcinoid (AC), and SCLC. Large cell 
neuroendocrine carcinoma (LCNEC) of the lung was officially identified by Travis et al. in 
1991 as a fourth category, a unique higher grade NSCLC existing between TC and SCLC 
(Travis et al., 1991). It is often difficult to diagnose LCNEC with small biopsy specimens 
because accurate diagnosis needs morphological and immunohistochemical information. 
Although earlier reports mainly focused on prognosis after surgical procedures, several 
recent studies reported on the efficacy of chemotherapy for advanced LCNEC. Because of 
the limited numbers of cases (in surgical series, LCNEC represents ~3% of lung cancers), 
large scale prospective studies have not been reported. Standard treatment for LCNEC, 
especially if advanced, is not established although LCNEC is included in NSCLC in the 
treatment algorithm in many guidelines. However, accumulating data including recent 
retrospective studies have suggested that there is similarity in the prognosis and treatment 
response between LCNEC and SCLC.  
In this review, we will focus on the treatment of advanced LCNEC for the better selection of 
chemotherapeutic regimens for the patients with this relatively rare lung cancer.  
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2. Large cell neuroendocrine carcinoma of the lung 
LCNEC is classified as a variant of large cell carcinoma in NSCLC whilst LCNEC has 
neuroendocrine characteristics similar to SCLC such as morphology and the 
immunohistochemical staining pattern. This discrepancy raises the question as to what the 
best therapeutic modality is, that is, should we treat LCNEC as NSCLC or SCLC? 
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Abbreviations: LCNEC, large cell neuroendocrine carcinoma;  
HPF, high power field;  
NSCLC, non-small cell lung carcinoma;  
N/C, nuclear-cytoplasmic ratio;  
NE, neuroendocrine 
Table 1. Tumors with neuroendocrine morphology (Travis 2010, Gollard et al., 2010) 
Recently, Varlotto et al. reported survival analysis of resected cases with LCNEC and SCLC 
(Varlotto et al., 2011). They compared overall survival (OS) and lung cancer-specific survival 
(LCSS) of patients with LCNEC and SCLC or other large cell lung carcinomas (OLCs) using 
the US National Cancer Institute database (SEER program). Although, the survival rates 
tended to be better in LCNEC and OLCs compared to SCLC, multivariate analysis showed 
no statistical differences (4-year OS rates are 41 % in LCNEC, 42% in OLC, and 32% in 
SCLC; 4-year LCSS rates are 57 % in LCNEC, 54% in OLC, and 42% in SCLC). The SEER 
database does not include chemotherapy information, so that we do not know the impact of 
chemotherapy on survival. Other reports also noted that survival in the early stage LCNEC 
is similar to SCLC (Asamura et al., 2006, Sun et al., 2009) and not better than NSCLC (Iyoda 
et al., 2007).  
3. Chemotherapy for advanced LCNEC 
LCNEC is classified in the category of NSCLC pathologically (Brambilla et al., 2001), so that 
the guideline recommended treatment of advanced LCNEC as NSCLC (NCCN guidelineTM 
2011), and many trials have included this disease as a NSCLC. However, recent 
accumulating data have brought new insights regarding possibly better results with SCLC 
regimens.  
From the published literature, we found four major studies showing the treatment results 
with chemotherapy for advanced LCNEC (Igawa et al., 2010, Fujiwara et al., 2007, Yamazaki 
et al., 2005, Rossi et al., 2005) (Table 2). All studies were retrospective and a total of 83 
patients were treated with first line systemic chemotherapy. Chemotherapy regimens can be 
classified into two groups: SCLC-based regimens (total n=44; platinum and etoposide n=27, 
platinum and irinotecan (CPT-11) n=16, CPT-11 only n=1) and NSCLC-based regimens 
(total n=39; platinum and paclitaxel (PTX) n=11, platinum and gemcitabine n=10, cisplatin 
with vindesine and mitomycin n=6, cisplatin and vindesine n=4, other platinum doublet 
n=2, other single agent n=6).  
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Abbreviations: OS, overall survival;  
Pt, patient number;  
RR response rate;  
PTX, paclitaxel;  
VNR, vinorelbine;  
DTX, docetaxel;  
MVP, mitomycin + vindesine + cisplatin;  
VDS, vindesine;  
GEM, gemcitabine.   
 
Table 2. Previous report regarding 1st line chemotherapy for advanced large cell 
neuroendocrine cell carcinoma (LCNEC) 
The response rate (RR) was 47.7% (21/44) for SCLC-based regimens and 35.9% (14/39) for 
NSCLC-based regimens (Table 3). In particular, a platinum doublet yielded a RR of 56.3% 
(9/16) with platinum and CPT-11, 44.4% (12/27) with platinum and etoposide, 54.5% (6/11) 
with platinum and PTX, 16.7% (2/12) with platinum and other third generation agents. 
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Rossi et al. (2005) showed a significant survival benefit with a SCLC-based regimen 
compared with a NSCLC regimen (OS of 51 months (M) vs 21M). This result is far better 
than other reports (OS 7.9M-10.3M, 1-year survival rate 35-47.6%), suggesting that the result 
was from combined effects of surgery and chemotherapy. 
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(Abbreviations are the same as in Table 1) 
Table 3. Summary of previous reports regarding 1st line chemotherapy for advanced large 
cell neuroendocrine cell carcinoma (LCNEC) 
As for second line treatment, there is no report other than a recent publication with 
amrubicin treatment (Yoshida et al., 2011). Amrubicin has efficacy for both SCLC and 
NSCLC, and has been used commonly in Japan in a second line setting with SCLC. 
Promising results for SCLC have also been recently reported from the USA (Ettinger et al., 
2010, Jotte et al., 2011).  
Currently there are a few prospective clinical trials for LCNEC in the 1st line settings 
(ClinicalTrials.gov and UMIN-CTR Clinical Trial, accessed 2nd Aug, 2011). One is not yet 
open but is an interesting phase II study with RAD001 + carboplatin/paclitaxel for 
advanced LCNEC. The other is an ongoing phase II study with cisplatin + irinotecan for 
advanced LCNEC.  
The former study with RAD001 is an interesting study utilizing an mTOR inhibitor which 
inhibits one of the signaling pathways, i.e. the PI3K-mTOR pathway, that lies downstream 
of receptor tyrosine kinases (RTKs) such as EGFR and c-MET. EGFR is one of the most   
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Table 4. Efficacy of Amrubicin in the 2nd line treatment for LCNEC and SCLC 
important RTKs in NSCLC (Paez et al., 2004), and moreover c-MET is reported to be an  
important RTK in SCLC as well as NSCLC (Nakachi et al., 2010, Rossi et al., 2005, Schmid et 
al., 2010). RAD001 has limited but apparent antitumor activity against pretreated SCLC as a 
single agent (Tarhini et al., 2010). According to these results, targeting signaling pathways 
with cytotoxic agent might be the next challenge for SCLC and LCNEC. Because many of 
the current effort in NSCLC is searching for driver mutations (Paez et al., 2004, Naoki et al., 
2002), such an effort is also important in SCLC and LCNEC.  
4. Conclusion 
Although there is an issue regarding accurate diagnosis with small biopsy specimens, 
accumulating retrospective data suggest that patients with advanced LCNEC will benefit 
from systemic chemotherapy.  
The current recommendation for the treatment of advanced LCNEC is similar to that of 
SCLC, i.e. platinum based combination chemotherapy, mainly with etoposide or CPT-11 
and possibly with PTX. Further prospective data is needed to elucidate the best combination 
therapy.  
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